Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Jeremy Abramson, Matthew Ku, Christopher Fox, Huiqiang Huang, Huilai Zhang, William Townsend, Dok Hyun Yoon, Won-Seog Kim, Haifaa Abdulhaq, Charles Herbaux, Jan Zaucha, Hung Chang, Estefania Mulvihill, Murali Kesavan, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Alessia Bottos, Linda Lundberg, Gareth P. Gregory
Institutions: Massachusetts General Hospital, The University of Melbourne, St Vincent's Hospital Melbourne, University of Nottingham, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, University College London, Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, University of California, San Francisco, Centre Hospitalier Universitaire de Montpellier, University Clinical Centre, Gdańsk Medical University, Chang Gung Memorial Hospital, Roche (Switzerland), Roche (United Kingdom), Monash Health, Monash University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417005241